Abstract
Human MDR1 encodes an ATP-binding cassette transporter, P-glycoprotein, that mediates multiple drug resistance (MDR) to antitumor agents. It has been previously shown that photoaffinity drug-labeling sites reside within, or near, the last transmembrane loop of each cassette within P-glycoprotein (transmembrane domains (TM) 5-6 and 11-12). A genetic approach was used to determine if the drug-labeling site in the second cassette contains functionally important amino acids. Since human MDR3 is 77% identical to MDR1 but does not mediate MDR, the region from TM10 to the C terminus of MDR1 was replaced with the corresponding sequences from MDR3. The resultant chimeric protein was expressed but not functional. By using progressively smaller replacements, we show that replacements limited to TM12 markedly impaired resistance to actinomycin D, vincristine, and doxorubicin, but not to colchicine. The phenotype was associated with an impaired ability to photoaffinity label the chimeric P-glycoprotein with [125I]iodoaryl azidoprazosin. In contrast, replacement of the loop between TM11 and 12 appears to create a more efficient drug pump for actinomycin D, colchicine, and doxorubicin, but not vincristine. These results suggest that, similar to voltage-gated ion channels, amino acids within and immediately N-terminal to the last transmembrane domain of P-glycoprotein compose part of the drug-binding pocket and are in close proximity to photoaffinity drug-labeling domains.
Highlights
From the Oncology and Immunology Research Section, Lederle Laboratories, American Cyanamid Company, Pearl River, New York 10965
Consistent with this, chimeric P-glycoproteins composed of human MDRI and MDR3 [34] or mouse mdrl and mdr2 [35], were defective or had altered ability to mediate multiple drug resistance (MDR) if a large span of transmembrane domains or the first intracytoplasmic loop from MDR3 replaced the corresponding region in MDRl, respectively
A clonal cell line derived from human melanoma cells was transfected with MDRI
Summary
Vol 270, No 10, Issue of March 10, pp. 5441-5448, 1995 Printed in U.S.A. Transmembrane 11 and 12 Form Part of the Drug-binding Domain in P-glycoprotein Encoded by MDRI*. Replacement of the loop between TM11 and 12 appears to create a more efficient drug pump for actinomycin D, colchicine, and doxorubicin, but not vincristine These results suggest that, similar to voltage-gated ion channels, amino acids within and immediately N-terminal to the last transmembrane domain of P-glycoprotein compose part of the drug-binding pocket and are in close proximity to photoaffinity drug-labeling domains. TM6 and the loop between TM5-6 (known as the H5, P, or SSl-SS2 region) of cassettes which compose voltagegated Ca 2+, Na +, and K+ channels form part of the ion pore and contain receptor sites for inhibitors and photoaffinity labeled drugs [9, 20,21,22] This may help explain why some agents, such as verapamil and azidopine, inhibit both P-glycoprotein and the L-type Ca2 + channel.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.